LMR Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.87M | Buy |
19,853
+3,385
| +21% | +$1.58M | 0.02% | 468 |
|
|
2025
Q4 | $7.47M | Buy |
16,468
+367
| +2% | +$158K | 0.01% | 476 |
|
|
2025
Q3 | $6.31M | Buy |
+16,101
| New | +$6.73M | 0.03% | 448 |
|
|
2025
Q2 | – | Sell |
-5,889
| Closed | -$2.86M | – | 1666 |
|
|
2025
Q1 | $2.86M | Sell |
5,889
-87,912
| -94% | -$41M | 0.03% | 573 |
|
|
2024
Q4 | $37.8M | Buy |
+93,801
| New | +$43.5M | 0.32% | 55 |
|
|
2024
Q2 | – | Sell |
-7,509
| Closed | -$3.14M | – | 1327 |
|
|
2024
Q1 | $3.14M | Sell |
7,509
-1,329
| -15% | -$562K | 0.03% | 447 |
|
|
2023
Q4 | $3.6M | Buy |
+8,838
| New | +$3.26M | 0.04% | 385 |
|
|
2023
Q1 | – | Sell |
-14,614
| Closed | -$4.22M | – | 1171 |
|
|
2022
Q4 | $4.22M | Sell |
14,614
-4,366
| -23% | -$1.33M | 0.07% | 305 |
|
|
2022
Q3 | $5.5M | Buy |
18,980
+4,928
| +35% | +$1.42M | 0.1% | 248 |
|
|
2022
Q2 | $3.96M | Buy |
14,052
+11,382
| +426% | +$3.05M | 0.07% | 330 |
|
|
2022
Q1 | $697K | Sell |
2,670
-44
| -2% | -$10.4K | 0.01% | 926 |
|
|
2021
Q4 | $596K | Sell |
2,714
-66,116
| -96% | -$12.9M | 0.01% | 860 |
|
|
2021
Q3 | $12.5M | Sell |
68,830
-55,640
| -45% | -$10.9M | 0.14% | 125 |
|
|
2021
Q2 | $25.1M | Buy |
124,470
+120,208
| +2,820% | +$25.1M | 0.38% | 51 |
|
|
2021
Q1 | $916K | Sell |
4,262
-11,727
| -73% | -$2.58M | 0.02% | 513 |
|
|
2020
Q4 | $3.78M | Buy |
15,989
+13,447
| +529% | +$3.09M | 0.06% | 125 |
|
|
2020
Q3 | $692K | Sell |
2,542
-41,532
| -94% | -$11.5M | 0.01% | 246 |
|
|
2020
Q2 | $12.8M | Buy |
+44,074
| New | +$11.9M | 0.32% | 52 |
|
|
2020
Q1 | – | Sell |
-12,477
| Closed | -$2.73K | – | 451 |
|
|
2019
Q4 | $2.73K | Buy |
12,477
+7,680
| +160% | +$1.55M | ﹤0.01% | 108 |
|
|
2019
Q3 | $813K | Buy |
4,797
+2,518
| +110% | +$445K | 0.04% | 202 |
|
|
2019
Q2 | $418K | Buy |
+2,279
| New | +$398K | 0.02% | 325 |
|
|
2019
Q1 | – | Sell |
-3,467
| Closed | -$575K | – | 466 |
|
|
2018
Q4 | $575K | Buy |
+3,467
| New | +$601K | 0.03% | 250 |
|
|
2018
Q3 | – | Sell |
-2,736
| Closed | -$465K | – | 516 |
|
|
2018
Q2 | $465K | Sell |
2,736
-7,896
| -74% | -$1.22M | 0.02% | 269 |
|
|
2018
Q1 | $1.59M | Hold |
10,632
| – | – | 0.16% | 122 |
|
|
2017
Q4 | $1.59M | Buy |
10,632
+5,292
| +99% | +$784K | 0.16% | 122 |
|
|
2017
Q3 | $812K | Sell |
5,340
-10,485
| -66% | -$1.58M | 0.09% | 126 |
|
|
2017
Q2 | $2.04M | Buy |
15,825
+1,636
| +12% | +$197K | 0.13% | 167 |
|
|
2017
Q1 | $1.55M | Buy |
+14,189
| New | +$1.25M | 0.15% | 97 |
|
|
2015
Q3 | – | Sell |
-15,507
| Closed | -$1.92M | – | 495 |
|
|
2015
Q2 | $1.92M | Buy |
15,507
+11,909
| +331% | +$1.5M | 0.23% | 114 |
|
|
2015
Q1 | $424K | Sell |
3,598
-4,488
| -56% | -$538K | 0.06% | 299 |
|
|
2014
Q4 | $961K | Buy |
+8,086
| New | +$911K | 0.13% | 213 |
|
Other funds holding VRTX
VCM
VPM
LMR Partners's VRTX Position: Q1 2026 in Review
LMR Partners increased its Vertex Pharmaceuticals (VRTX) stake by 21% in Q1 2026, buying an estimated $1.58M and bringing the position to 19,853 shares worth $8.87M. The position accounts for 0.02% of the portfolio, ranked #468.
LMR Partners first reported a position in VRTX in Q4 2014 and has held it in 31 quarters since. The position peaked at $37.8M in Q4 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- LMR Partners held 19,853 shares of Vertex Pharmaceuticals worth $8.87M as of Q1 2026.
- LMR Partners bought 3,385 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.58M.
- Vertex Pharmaceuticals made up 0.02% of LMR Partners's portfolio in Q1 2026, its #468 holding.
- LMR Partners first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 31 quarters since.
- LMR Partners's Vertex Pharmaceuticals position peaked at $37.8M in Q4 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.